Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view
Authors:
- 10 January 2015
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 50 (1) , 67-71
Abstract
A growing body of evidence is challenging the indiscriminate use of postoperative radioiodine for remnant ablation (RRA) in low-risk (LR) differentiated thyroid cancer patients. We critically reviewed the current evidence on which the rationale for RRA is based for LR patients and analyzed the new evidence-based recommendations for LR patients from the draft of the 2015 American Thyroid Association (ATA) guidelines. Cost-effective tools for staging and follow-up, such as neck ultrasonography and serial thyroglobulin testing, are useful for monitoring non-RRA-treated patients. Recurrence rates are very low in non-RRA-treated LR patient cohorts. Most RRA side effects are mild and transient, but can impair a patient’s quality of life. RRA is appropriately not routinely recommended in LR patients according to the draft 2015 ATA guidelines and should be reserved for higher-risk patients.Keywords
This publication has 33 references indexed in Scilit:
- The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?Clinical Endocrinology, 2014
- Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement?The Journal of Clinical Endocrinology & Metabolism, 2012
- Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancerClinical Endocrinology, 2011
- Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapyCancer, 2011
- Value of Postoperative Thyroglobulin and Ultrasonography for the Indication of Ablation and 131 I Activity in Patients with Thyroid Cancer and Low Risk of RecurrenceThyroid®, 2011
- Excellent Prognosis of Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma Who Underwent Thyroidectomy and Elective Lymph Node Dissection Without Radioiodine TherapyWorld Journal of Surgery, 2009
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Long‐term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatmentClinical Endocrinology, 2008
- A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivorsClinical Endocrinology, 2007
- Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.1986